Will Shrank, MD

Will Shrank, MD, breaks down why payers, providers, and manufacturers are all struggling to keep pace with a rapidly expanding cell and gene therapy pipeline — and what it will take to fix it.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.